BBA
EVFM

Baker Bros. Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Baker Bros. Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,583,616
Closed -$2.92M – 128
2022
Q2 		$2.92M Buy
+2,583,616
New +$4.26M 0.02% 90
2022
Q1 		– Sell
-179,807
Closed -$1.01M – 121
2021
Q4 		$1.01M Hold
179,807
– – ﹤0.01% 117
2021
Q3 		$1.99M Hold
179,807
– – 0.01% 112
2021
Q2 		$3.05M Hold
179,807
– – 0.01% 104
2021
Q1 		$4.72M Buy
179,807
+152,381
+556% +$6.93M 0.02% 96
2020
Q4 		$991K Sell
27,426
-1,444
-5% -$52.2K ﹤0.01% 118
2020
Q3 		$1.02M Sell
28,870
-66,130
-70% -$2.87M ﹤0.01% 112
2020
Q2 		$4.03M Buy
95,000
+53,580
+129% +$3.61M 0.02% 83
2020
Q1 		$3.31M Sell
41,420
-9,034
-18% -$723K 0.02% 76
2019
Q4 		$4.67M Buy
50,454
+43,651
+642% +$3.68M 0.02% 71
2019
Q3 		$514K Buy
+6,803
New +$522K ﹤0.01% 104

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Baker Bros. Advisors's EVFM Position: Q3 2022 in Review

Baker Bros. Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 2,583,616 shares — an estimated $2.92M sold.

Baker Bros. Advisors first reported a position in EVFM in Q3 2019 and held it in 11 quarters. The position peaked at $4.72M in Q1 2021. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Baker Bros. Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,583,616 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $2.92M.
  • Baker Bros. Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Baker Bros. Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $4.72M in Q1 2021.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.